In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% ...
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with ...
1don MSN
Judge: Turkish student who criticized Israel can resume research at Tufts after visa revocation
A federal judge has allowed a Tufts University student from Turkey to resume research and teaching while she challenges her ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback